Litcius/Paper detail

LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen

Eric Van Cutsem, Maria Di Bartolomeo, E.C. Smyth, Ian Chau, H. Park, Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer A. Ajani, Joseph Chao, J. Seraj, Yoshiaki Kawaguchi, A. Qin, Jasmeet Singh, Gudrun Meinhardt, Geoffrey Y. Ku

2021Annals of Oncology28 citationsDOI

Topics & Concepts

MedicineTrastuzumabGastroesophageal JunctionInternal medicineOncologyCancerPhases of clinical researchClinical trialAdenocarcinomaBreast cancerGastric Cancer Management and OutcomesHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research
LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen | Litcius